证券代码：000516 证券简称：国际医学 公告编号：2025-047 该制度同日登载于巨潮资讯网（www.cninfo.com.cn）。 1 西安国际医学投资股份有限公司 第十三届董事会第八次会议决议 公 告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司董事会于2025年10月17日以书 面方式发出召开公司第十三届董事会第八次会议的通知，并于2025年 10月28日在公司总部会议室以现场表决形式召开。会议应到董事9人， 实到董事9人，出席会议的董事有史今、刘旭、曹建安、刘瑞轩、孙 文国、师萍、张宝通、李成、付强。会议的召开符合有关法律法规、 规章和《公司章程》的规定。会议由史今董事长主持。 经会议认真审议和投票表决，通过了下述决议： 一、通过公司《2025 年第三季度报告》（9 票同意、0 票反对、 0 票弃权）； 二、通过《关于修改〈外部信息报送和使用管理制度〉的议案》 （9 票同意、0 票反对、0 票弃权）； 该制度同日登载于巨潮资讯网（www.cninfo.com.cn）。 三、通过《关于修改〈董事会秘书工作细则〉的议案 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥961,129,633.01, a decrease of 18.95% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥128,694,712.92, representing a decline of 234.24% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥122,578,844.09, down 52.03% from the previous year[5]. - Total operating revenue for the period was CNY 2,995,437,323.47, a decrease of 16.9% compared to CNY 3,606,256,924.42 in the previous period[17]. - The company reported a net loss of CNY 273,684,991.31, compared to a profit of CNY 19,971,552.10 in the previous period[15]. - The net profit for the current period is -374,029,115.97, compared to -294,272,771.90 in the previous period, indicating a decline of approximately 27.1%[18]. - Operating profit for the current period is -360,502,200.22, worsening from -283,406,415.63 in the previous period, reflecting a decline of about 27.2%[18]. - The total comprehensive income attributable to the parent company is -293,656,543.41, compared to -212,108,983.83 in the previous period, reflecting a decline of approximately 38.4%[19]. Cash Flow and Assets - Cash flow from operating activities for the year-to-date increased by 47.67%, totaling ¥921,003,855.55[5]. - The company's cash and cash equivalents decreased to CNY 331,072,769.68 from CNY 590,562,003.38, representing a decline of 43.9%[13]. - Cash and cash equivalents at the end of the period decreased to 243,072,769.68 from 427,482,946.42, a decline of about 43.1%[22]. - Investment activities generated a net cash outflow of -147,160,133.41, improving from -406,156,113.17 in the previous period[22]. - Total assets at the end of the reporting period were ¥9,790,656,512.89, a decrease of 7.95% from the end of the previous year[5]. - Total assets decreased to CNY 9,790,656,512.89 from CNY 10,636,321,992.89, reflecting a decline of 7.9%[15]. - Total liabilities decreased to CNY 6,736,386,171.04 from CNY 7,164,331,951.87, a decrease of 6.0%[15]. - The company's equity attributable to shareholders decreased to CNY 3,337,580,628.58 from CNY 3,674,927,755.19, a decline of 9.2%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 103,208[10]. - The largest shareholder, Shaanxi Century New Yuan Commercial Management Co., Ltd., held 27.52% of the shares, amounting to 616,061,198 shares[10]. Expenses - Sales expenses increased by 78.56% year-to-date, primarily due to increased promotional costs[8]. - Research and development expenses rose to 6,045,483.10 from 5,715,774.18, an increase of approximately 5.8%[18]. - Financial expenses decreased to 111,183,899.06 from 130,194,846.46, a reduction of about 14.6%[18]. Earnings Per Share - The company's basic and diluted earnings per share were both -¥0.0572, a decrease of 207.53% year-on-year[5]. - The basic and diluted earnings per share for the current period are both -0.1302, compared to -0.0954 in the previous period, indicating a decline of approximately 36.6%[19].

| | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-27 | 4.89 0.41% | 109.62万 | 1.65% | 109.89万 | 1.66% | -219.50万 | -3.31% | | 2025-10-24 | 4.87 -0.41% | 389.32万 | 8.11% | -66.54万 | -1.39% | -322.79万 | -6.72% | | 2025-10-23 | 4.89 0.20% | 170.77万 | 3.48% | -277.80万 | -5.65% | 107.03万 | 2.18% | | 2025-10-22 | 4.88 0.41% | 443.26万 | 7.37% | -412.30万 | -6.86% | -30.96万 | -0.52% | | 2025-10-21 | 4.86 0.62% | -226.12万 | -3.83% | 260.42万 | 4.42% ...

证券代码：000516 证券简称：国际医学 公告编号：2025-046 二、控股股东及其一致行动人股份累计质押的基本情况 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | | | | 本次质 | 本次质 | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 押前质 | 押后质 | 占其 | 占公 | 情况 | | 情况 | | | 股东 | 持股数量 | 持股 | | | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | | | | 押股份 | 押股份 | | | | | | | | 名称 | （股） | 比例 | | | 股份 | 股本 | 份限售和 | 质押 | 份限售和 | 质押 | | | | | 数量 | 数量 | 比例 | 比例 | | | | | | | | | （股） | （股） | | | 冻结数量 | 股份 | 冻结数量 | 股份 | | | | | | | | | （股） | 比例 | （股） | 比例 ...

Core Insights - The third China-Korea (Jinan) Health Industry New Technology Enterprise Exchange event was held to deepen cooperation in the health sector between China and South Korea [1][10] - Several collaborative projects were signed, including new drug development for muscle-wasting metabolic diseases and innovative dental implant production [3][10] Group 1: Event Overview - The event was organized by Jinan International Medical Center, Shandong First Medical University, and the Korea Small and Medium Enterprises Agency [1] - The event showcased significant achievements in China-Korea health industry cooperation [3] Group 2: Collaborative Projects - New projects include the establishment of a production base for innovative dental implants and the production of new materials for urinary catheters [3] - Mitos and Dedawei companies shared successful experiences of collaboration, enhancing confidence among Korean companies to invest in China [5] Group 3: Technology Showcase - Ten Korean companies presented advanced technologies in areas such as cell and gene therapy, innovative dental implants, and smart medical devices [7] - The presentations highlighted the innovative vitality and potential of the health industry, laying a foundation for further cooperation [7] Group 4: Financial Collaboration - A China-Korea enterprise and financial institution matchmaking session was held, involving multiple investment institutions from both countries [8] - Financial institutions played a crucial role in facilitating cooperation by providing a stable and efficient financial platform [8] Group 5: Future Outlook - The successful hosting of the event is expected to inject new vitality and strong momentum into the cooperation between the two countries in the health industry [10] - Both countries aim to continue working together to create a promising future for the health industry [10]

Core Viewpoint - The company is focusing on enhancing operational efficiency and service quality in response to industry policy changes, particularly in medical insurance payment reforms [1] Group 1: Company Strategy - The company plans to strengthen cost control and improve operational efficiency while expanding service scale in a structured manner [1] - A differentiated strategy will be employed to build competitive advantages and enhance service value [1] - The company aims to optimize its capital structure through diversified financing channels to improve debt structure and reduce financial costs [1] Group 2: Financial Performance - As of October 21, 2025, the company's stock closed at 4.86 yuan, with a 0.62% increase and a trading volume of 12.17 million shares, amounting to a transaction value of 58.96 million yuan [1] - The company's current asset-liability ratio is considered reasonable, and it has sufficient comprehensive credit exposure [1] Group 3: Project Updates - The proton therapy center at Xi'an International Medical Center Hospital, the first of its kind in Northwest China, is under construction and will commence operations upon obtaining necessary administrative approvals [1] Group 4: Market Sentiment - On October 21, the main funds experienced a net outflow of 2.26 million yuan, accounting for 3.84% of the total transaction value [2] - Retail investors saw a net outflow of 0.34 million yuan, representing 0.58% of the total transaction value [2]

Core Viewpoint - International Medical (000516) has shown a mixed performance in recent trading sessions, with fluctuations in stock price and varying capital flows, indicating potential volatility in investor sentiment [1][2]. Financial Performance - As of the latest report, International Medical's total market value is 10.881 billion yuan, with a net asset value of 3.21 billion yuan [3]. - The company reported a net profit of -165 million yuan, reflecting a year-on-year increase of 4.98%, while its main revenue decreased by 15.95% to 2.034 billion yuan [3]. - The gross profit margin stands at 7.8%, significantly lower than the industry average of 35.92% [3]. Capital Flow Analysis - On October 21, 2025, the stock price closed at 4.86 yuan, with a slight increase of 0.62%. The main capital flow showed a net outflow of 2.2612 million yuan, accounting for 3.83% of the total transaction volume [1][2]. - Over the past five days, the stock has experienced varying capital flows, with notable net inflows from speculative funds on certain days, while main capital has seen consistent outflows [2]. Industry Comparison - In comparison to the healthcare services industry, International Medical ranks low in several key metrics, including net profit and return on equity (ROE), with a ROE of -4.6% compared to the industry average of 2.19% [3]. - The company's price-to-earnings ratio (P/E) is -32.98, indicating a lack of profitability relative to its peers [3]. Analyst Ratings - Recently, two institutions have provided ratings for the stock, with one buy rating and one hold rating, suggesting a cautious outlook among analysts [4].

证券日报网讯国际医学10月21日在互动平台回答投资者提问时表示，国际化战略一直是国际医学发展规 划重要方向之一。国际医学的国际化不仅仅体现在业内领先的硬件设备，更是在医院资质、诊疗标准、 诊疗模式、服务流程、人才培养、科研创新和学术交流等方面的国际化，最终使患者在"家门口"就能享 受到国际化的优质医疗服务。围绕既定战略方向和发展需求，国际医学在挖掘全球优质医疗资源、拓展 国际合作方面进行了诸多探索与尝试，积极参与国际行业会议，组织海内外调研，并与欧洲、美洲、亚 洲及港澳台地区的知名医疗机构、高校、科技公司等进行了广泛的联络与交流。未来，国际医学将在现 有国际化布局基础上，打造卓越中心和优势专科；积极推动医教研的深度融合、协同发展；加强团队建 设和国际人才引进；提升企业精益管理水平。 （文章来源：证券日报） ...

Core Viewpoint - International Medical (000516) experienced a decline in stock price, closing at 4.91 yuan on October 16, 2025, with a drop of 1.21% and a trading volume of 107,800 hands, resulting in a transaction amount of 53.16 million yuan [1] Financial Performance - The company reported a total revenue of 2.034 billion yuan for the first half of 2025, a year-on-year decrease of 15.95% [3] - The net profit attributable to shareholders was -165 million yuan, an increase of 4.98% year-on-year [3] - The net profit after deducting non-recurring items was -189 million yuan, a decrease of 36.09% year-on-year [3] - In Q2 2025, the company’s revenue was 1.037 billion yuan, down 16.86% year-on-year, while the net profit attributable to shareholders was -58.61 million yuan, up 14.68% year-on-year [3] Market Position and Ratios - The total market capitalization of International Medical is 10.993 billion yuan, ranking 12th in the medical services industry [3] - The company has a net asset value of 3.21 billion yuan, ranking 14th in the industry [3] - The company’s net profit margin is -10.73%, ranking 38th in the industry [3] - The return on equity (ROE) stands at -4.6%, ranking 39th in the industry [3] Recent Trading Activity - On October 16, 2025, the main funds experienced a net outflow of 1.4728 million yuan, accounting for 2.77% of the total transaction amount [1] - Retail investors saw a net outflow of 52,100 yuan, representing 0.1% of the total transaction amount [1] - Over the past five days, the stock has seen fluctuations in net inflows and outflows from different investor categories, indicating varying levels of market interest [2]

Core Viewpoint - The company is experiencing a decline in revenue and performance due to tightening medical policies, anti-corruption measures, and a decrease in inpatient numbers, while outpatient services are growing [2]. Group 1: Company Performance - As of October 15, 2025, the company's stock closed at 4.97 yuan, with a 0.61% increase and a trading volume of 12.12 million shares, amounting to a transaction value of 60.07 million yuan [1]. - The company reported a main business revenue growth rate of -17.24%, with a significant drop in industry ranking by 55.56%, indicating weakened competitiveness [2]. - The company's liquidity ratio stands at 28.16%, placing it in the bottom 3.7% of the industry, reflecting weak competitive strength [2]. Group 2: Strategic Response - The company plans to enhance its competitive advantage through a differentiated strategy, focusing on service value addition and business structure adjustment [2]. - Future initiatives include expanding into aesthetic medicine, rehabilitation, women's and children's health, health management, traditional Chinese medicine, assisted reproduction, mental health, and specialized services [2]. - The company aims to optimize resource allocation, merge departments, strengthen cost control, and improve financial management of pharmaceuticals and consumables [2]. Group 3: Market Activity - On October 15, the net inflow of main funds was 228,300 yuan, accounting for 0.38% of the total transaction value [3]. - Retail investors experienced a net outflow of 1,838,100 yuan, representing 3.06% of the total transaction value [3].